Suppr超能文献

利用辅料增强生长作用将气溶胶沉积到肺部气道及其中。

Targeting aerosol deposition to and within the lung airways using excipient enhanced growth.

机构信息

1 Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University , Richmond, VA 23284.

出版信息

J Aerosol Med Pulm Drug Deliv. 2013 Oct;26(5):248-65. doi: 10.1089/jamp.2012.0997. Epub 2013 Jan 3.

Abstract

BACKGROUND

Previous studies have characterized the size increase of combination submicrometer particles composed of a drug and hygroscopic excipient when exposed to typical airway thermodynamic conditions. The objective of this study was to determine the deposition and size increase characteristics of excipient enhanced growth (EEG) aerosols throughout the tracheobronchial (TB) airways and to evaluate the potential for targeted delivery.

METHODS

Submicrometer particles composed of a poorly water-soluble drug (insulin) and hygroscopic excipient (sodium chloride) were considered at drug:excipient mass ratios of 50:50 and 25:75. A previously validated computational fluid dynamics model was used to predict aerosol size increase and deposition in characteristic geometries of the mouth-throat (MT), upper TB airways through the third bifurcation (B3), and remaining TB airways through B15. Additional validation experiments were also performed for albuterol sulfate:mannitol particles. Both growth of combination particles and deposition are reported throughout the conducting airways for characteristic slow and deep (SD) and quick and deep (QD) inhalations.

RESULTS

For all EEG cases considered, MT deposition was less than 1% of the drug dose, which is at least one order of magnitude lower than with state-of-the-art and conventional inhalers. Final aerosol sizes exiting the TB region and entering the alveolar airways were all greater than 3 μm. For SD inhalation, deposition fractions of 20% were achieved in the lower TB region of B8-B15, which is a factor of 20-30×higher than conventional delivery devices. With QD inhalation, maximum alveolar delivery of 90% was observed.

CONCLUSIONS

Increasing the dose delivered to the lower TB region by a factor of 20-30×or achieving 90% delivery to the alveolar airways was considered effective aerosol targeting compared with conventional devices. The trend of higher flow rates resulting in better alveolar delivery of aerosols is unique to EEG and may be used to design highly efficient dry powder inhalers.

摘要

背景

先前的研究已经描述了由药物和吸湿性赋形剂组成的组合亚微米颗粒在暴露于典型气道热力学条件下的粒径增大情况。本研究的目的是确定赋形剂增强生长(EEG)气溶胶在整个气管支气管(TB)气道中的沉积和粒径增大特性,并评估其靶向输送的潜力。

方法

考虑了由疏水性药物(胰岛素)和吸湿性赋形剂(氯化钠)组成的亚微米颗粒,药物:赋形剂质量比为 50:50 和 25:75。使用先前验证的计算流体动力学模型来预测在口腔-咽喉(MT)、上 TB 气道至第三分支(B3)以及剩余 TB 气道至 B15 的特征几何结构中气溶胶的粒径增大和沉积。还针对硫酸沙丁胺醇:甘露醇颗粒进行了额外的验证实验。对于特征性的缓慢而深(SD)和快速而深(QD)吸入,均报告了组合颗粒的生长和沉积在整个传导气道中的情况。

结果

对于所有考虑的 EEG 情况,MT 沉积都不到药物剂量的 1%,比最先进的和常规的吸入器至少低一个数量级。从 TB 区域排出并进入肺泡气道的最终气溶胶粒径均大于 3μm。对于 SD 吸入,在 B8-B15 的下 TB 区域实现了 20%的沉积分数,这是常规输送装置的 20-30 倍。对于 QD 吸入,观察到最大肺泡输送 90%。

结论

与常规装置相比,将下 TB 区域的输送剂量提高 20-30 倍或实现 90%的肺泡输送被认为是有效的气溶胶靶向。较高的气流速率导致更好的肺泡输送气溶胶的趋势是 EEG 特有的,可用于设计高效的干粉吸入器。

相似文献

1
Targeting aerosol deposition to and within the lung airways using excipient enhanced growth.
J Aerosol Med Pulm Drug Deliv. 2013 Oct;26(5):248-65. doi: 10.1089/jamp.2012.0997. Epub 2013 Jan 3.
7
Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs.
J Pharm Sci. 2016 Jan;105(1):147-59. doi: 10.1016/j.xphs.2015.11.027. Epub 2016 Jan 13.
8
In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition.
J Aerosol Med Pulm Drug Deliv. 2013 Jun;26(3):145-56. doi: 10.1089/jamp.2012.0989. Epub 2012 Oct 1.
9
In silico investigation of inhalation condition impacts on hygroscopic growth and deposition of salbutamol sulphate in human airways.
Respir Physiol Neurobiol. 2024 Aug;326:104271. doi: 10.1016/j.resp.2024.104271. Epub 2024 May 3.
10
Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler.
J Aerosol Med Pulm Drug Deliv. 2015 Jun;28(3):189-201. doi: 10.1089/jamp.2014.1158. Epub 2014 Sep 5.

引用本文的文献

1
Particle surface coating for dry powder inhaler formulations.
Expert Opin Drug Deliv. 2025 May;22(5):711-727. doi: 10.1080/17425247.2025.2482052. Epub 2025 Mar 26.
3
Characterization of Pediatric Extrathoracic Aerosol Deposition with Air-Jet Dry Powder Inhalers.
J Aerosol Sci. 2025 Jan;183. doi: 10.1016/j.jaerosci.2024.106474. Epub 2024 Sep 28.
4
Recent Developments in Aerosol Pulmonary Drug Delivery: New Technologies, New Cargos, and New Targets.
Annu Rev Biomed Eng. 2024 Jul;26(1):307-330. doi: 10.1146/annurev-bioeng-110122-010848. Epub 2024 Jun 20.
6
Analysis of Nasal Interface Options for High-Efficiency Aerosol Administration to Preterm Infants.
J Aerosol Med Pulm Drug Deliv. 2022 Aug;35(4):196-211. doi: 10.1089/jamp.2021.0057. Epub 2022 Feb 14.
8
Advancement of the Infant Air-Jet Dry Powder Inhaler (DPI): Evaluation of Different Positive-Pressure Air Sources and Flow Rates.
Pharm Res. 2021 Sep;38(9):1615-1632. doi: 10.1007/s11095-021-03094-w. Epub 2021 Aug 30.
9
Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics.
Adv Drug Deliv Rev. 2021 Sep;176:113901. doi: 10.1016/j.addr.2021.113901. Epub 2021 Jul 29.

本文引用的文献

3
Production of Inhalable Submicrometer Aerosols from Conventional Mesh Nebulizers for Improved Respiratory Drug Delivery.
J Aerosol Sci. 2012 Sep;51:66-80. doi: 10.1016/j.jaerosci.2012.04.002. Epub 2012 Apr 14.
5
In vitro tests for aerosol deposition. I: Scaling a physical model of the upper airways to predict drug deposition variation in normal humans.
J Aerosol Med Pulm Drug Deliv. 2012 Feb;25(1):32-40. doi: 10.1089/jamp.2011.0905. Epub 2011 Nov 9.
8
Numerical Model to Characterize the Size Increase of Combination Drug and Hygroscopic Excipient Nanoparticle Aerosols.
Aerosol Sci Technol. 2011 Jan 1;45(7):884-899. doi: 10.1080/02786826.2011.566592.
9
In silico models of aerosol delivery to the respiratory tract - development and applications.
Adv Drug Deliv Rev. 2012 Mar 30;64(4):296-311. doi: 10.1016/j.addr.2011.05.009. Epub 2011 May 27.
10
Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.
J Aerosol Med Pulm Drug Deliv. 2011 Aug;24(4):175-82. doi: 10.1089/jamp.2010.0855. Epub 2011 Mar 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验